预约演示
更新于：2026-06-06
Methohexital Sodium
美索比妥
更新于：2026-06-06
概要
基本信息
药物类型 小分子化药 |
别名 (±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid、5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione、5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione + [8] |
作用方式 拮抗剂 |
作用机制 GABAA receptor拮抗剂(γ-氨基丁酸 A 受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1960-06-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H18N2NaO3 |
InChIKeyZNCHEYWRDOJPAW-UHFFFAOYSA-N |
CAS号309-36-4 |
关联
7
项与 美索比妥 相关的临床试验ChiCTR2500113973
A Study on Brain Imaging and Blood Biomarkers of Non-invasive Neuromodulation Therapy for Depression Patients
NCT05655754
A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy
NCT04187196
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
100 项与 美索比妥 相关的临床结果
登录后查看更多信息
100 项与 美索比妥 相关的转化医学
登录后查看更多信息
100 项与 美索比妥 相关的专利（医药）
登录后查看更多信息
1,505
项与 美索比妥 相关的文献（医药）2025-08-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Propofol Versus Methohexital in Electroconvulsive Therapy: Impact on Treatment Efficacy and Adverse Effects. A Systematic Literature Review and Meta‐Analysis
Review
作者: Ahlmén‐Laiho, Ulla ; Saari, Tom ; Huoponen, Saara H. ; Sisa, Katrin ; Taittonen, Markku
ABSTRACT:
Background:
Electroconvulsive therapy (ECT) is a widely used treatment for depression, but the choice of the anesthetic that is used for induction may affect both clinical outcomes and the occurrence of adverse effects (AEs). Propofol and methohexital are frequently used in Finland, yet their relative impact on treatment efficacy and AEs remains uncertain.
Methods:
We conducted a systematic literature review and meta‐analysis following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Electronic databases were searched up to January 21, 2025. Studies comparing propofol and methohexital in adult patients receiving ECT for depression and utilizing numeric scales for depression assessment were included. The primary outcome was the clinical treatment response, defined by the number of ECT sessions required to achieve remission. The secondary outcome was the variation of AEs associated with ECT between comparator groups.We included eight studies in the final analysis with 194 patients in the propofol group and 198 patients in the methohexital group. Five of the studies were randomized controlled trials and three were retrospective cohort studies. Three randomized controlled trials with 131 patients: 62 (47%) in propofol group and 69 (53%) in methohexital group were included in meta‐analysis.
Results:
The number of ECT sessions required for recovery did not differ between groups. All studies demonstrated effective alleviation of depression through ECT, regardless of anesthetic choice. However, AEs were inconsistently reported, and a comprehensive overview of the topic was not possible.
Conclusions:
Low‐quality evidence suggests equal efficacy of propofol compared to methohexital with regard to clinical remission of depression after ECT.
Systematic Review Registration:
Trial Registration: PROSPERO; CRD42024520709.
Editorial Comment:
This systematic review and meta‐analysis presents the available but limited and low‐quality evidence in this study area, and supports an interpretation that propofol and methohexital have similar efficacy when facilitating electroconfulsive therapy as treatment for depression, to relieve depression symptoms.
2025-06-01NEUROBIOLOGY OF DISEASE
Exploring potential key genes and disease mechanisms in early-onset genetic epilepsy via integrated bioinformatics analysis
Article
作者: Efthimiopoulos, Spiros ; Boulaki, Vasiliki ; Spyrou, George Μ ; Moschonas, Nicholas K
Epilepsy is a severe common neurological disease affecting all ages. Epilepsy with onset before the age of 5 years, designated early-onset epilepsy (EOE), is of special importance. According to previous studies, genetic factors contribute significantly to the pathogenesis of EOE that remains unclear and must be explored. So, a list of 229 well-selected EOE-associated genes expressed in the brain was created for the investigation of genetic factors and molecular mechanisms involved in its pathogenesis. Enrichment analysis showed that among significant pathways were nicotine addiction, GABAergic synapse, synaptic vesicle cycle, regulation of membrane potential, cholinergic synapse, dopaminergic synapse, and morphine addiction. Performing an integrated analysis as well as protein-protein interaction network-based approaches with the use of GO, KEGG, ClueGO, cytoHubba and 3 network metrics, 12 hub genes were identified, seven of which, CDKL5, GABRA1, KCNQ2, KCNQ3, SCN1A, SCN8A and STXBP1, were identified as key genes (via Venn diagram analysis). These key genes are mostly enriched in SNARE interactions in vesicular transport, regulation of membrane potential and synaptic vesicle exocytosis. Clustering analysis of the PPI network via MCODE showed significant functional modules, indicating also other pathways such as N-Glycan biosynthesis and protein N-linked glycosylation, retrograde endocannabinoid signaling, mTOR signaling and aminoacyl-tRNA biosynthesis. Drug-gene interaction analysis identified a number of drugs as potential medications for EOE, among which the non-FDA approved drugs azetukalner (under clinical development), indiplon and ICA-105665 and the FDA approved drugs retigabine, ganaxolone and methohexital.
2025-06-01JOURNAL OF ECT
A Survey of ECT Anesthesia Practice Variation in Finland
Article
作者: Huoponen, Saara H. ; Sisa, Katrin ; Taittonen, Markku ; Saari, Tom ; Ahlmén-Laiho, Ulla ; Huoponen, Saara H
Objective:
This study examines the extent of variation in anesthesia practices among Finnish neuromodulation units providing electroconvulsive therapy (ECT) and investigates recent changes within individual units.
Methods:
An electronic survey was carried out among Finnish neuromodulation units exploring staff demographics, anesthesia practices (including agents and adjuvants), patient physiology monitoring, observed adverse effects, patient follow-up times, and recent anesthesia protocol changes.
Results:
Finland has 26 neuromodulation units providing ECT, of which 18 (69%) responded to our study. The research uncovered significant differences in anesthesia practices, including induction agent choice, convulsion motor component monitoring, staff educational backgrounds, and reported adverse effects. Propofol was the most commonly used anesthetic in 14 units (78%). Three units (17%) reported using methohexital in 80%–100% of their patients, whereas in contrast, methohexital was not used at all in 10 units (56%). Electromyography seizure activity was quantitatively measured in 6 units (33%), whereas 10 units (56%) did not measure electromyography seizure activity at all. The remaining 2 units assessed seizure activity through visual observation. Headache requiring medication was the most commonly reported adverse effect, and it was reported as a frequent problem in 3 units (18%).
Conclusions:
Based on the variation in anesthesia practices identified in the study, we suggest there may be benefits to developing a national guideline for standardizing treatment.
1
项与 美索比妥 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 美索比妥 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1960-06-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 73 | (Sedation With Propofol Group) | 淵範選鬱鏇醖襯壓鏇願(蓋窪網鬱遞繭築網鑰夢) = 繭夢廠遞繭糧鹹艱艱壓 鏇膚蓋艱衊鬱鏇鏇衊簾 (鬱鹽構鬱選構網艱選願, 鏇願願衊憲製繭構鹹獵 ~ 餘蓋繭膚襯膚糧鑰淵範) 更多 | - | 2023-11-13 | ||
(Sedation With Methohexital Group) | 淵範選鬱鏇醖襯壓鏇願(蓋窪網鬱遞繭築網鑰夢) = 繭糧壓獵衊網餘夢範觸 鏇膚蓋艱衊鬱鏇鏇衊簾 (鬱鹽構鬱選構網艱選願, 艱襯構鏇淵選鬱窪醖獵 ~ 餘鬱觸願簾觸衊選鏇鏇) 更多 | ||||||
临床4期 | 73 | 選鏇簾遞淵遞壓鹽選築(獵蓋鬱觸積醖築構憲鹹) = 壓餘網積築餘簾觸衊夢 蓋顧鏇糧蓋醖衊構鬱鑰 (醖獵糧鹽壓膚顧遞選鹹 ) 更多 | - | 2022-09-21 | |||
選鏇簾遞淵遞壓鹽選築(獵蓋鬱觸積醖築構憲鹹) = 繭築糧糧構願繭遞製夢 蓋顧鏇糧蓋醖衊構鬱鑰 (醖獵糧鹽壓膚顧遞選鹹 ) 更多 | |||||||
N/A | 51 | (Methohexital) | 廠範膚構鏇淵鑰簾鏇獵 = 鑰窪鏇窪窪構構蓋廠鬱 築鑰選襯構鑰獵齋顧齋 (築鑰繭齋願鏇簾簾選夢, 製憲遞廠範範糧艱鏇淵 ~ 窪衊範製築構選構選蓋) 更多 | - | 2019-03-13 | ||
(Propofol) | 廠範膚構鏇淵鑰簾鏇獵 = 糧構鹽膚鹽鹹壓簾顧簾 築鑰選襯構鑰獵齋顧齋 (築鑰繭齋願鏇簾簾選夢, 夢廠淵襯窪壓齋鑰製觸 ~ 積觸憲遞積夢糧蓋衊製) 更多 | ||||||
临床4期 | - | 138 | (Bilateral ECT Mecta 5000M) | 鹹憲築獵窪鹽築構製獵(觸夢廠餘襯網醖餘觸膚) = 淵顧壓壓壓憲選蓋構鹹 鹹遞簾願構鹽製選繭網 (齋壓膚鑰壓壓窪糧網夢, 6.3) 更多 | - | 2018-11-14 | |
(High-dose Unilateral ECT Mecta 5000M) | 鹹憲築獵窪鹽築構製獵(觸夢廠餘襯網醖餘觸膚) = 獵範齋廠窪網夢壓簾鏇 鹹遞簾願構鹽製選繭網 (齋壓膚鑰壓壓窪糧網夢, 6.1) 更多 | ||||||
N/A | 20 | (Ketamine Inductions) | 鹽遞積製淵鏇醖憲壓網(憲構膚範壓蓋獵範鬱遞) = 膚襯鹽淵蓋鏇鏇淵觸醖 廠夢廠顧襯繭觸鏇獵艱 (廠願襯襯襯醖選選範衊, 1.6) 更多 | - | 2014-12-30 | ||
(Methohexital Inductions) | 鹽遞積製淵鏇醖憲壓網(憲構膚範壓蓋獵範鬱遞) = 積鹽觸膚鹹鬱鑰衊憲鹽 廠夢廠顧襯繭觸鏇獵艱 (廠願襯襯襯醖選選範衊, 1.6) 更多 | ||||||
N/A | - | 222 | Methohexital/remifentanil | 積繭構鑰膚淵積衊糧淵(艱鹹選膚遞壓艱憲鬱鏇) = 憲窪醖衊顧淵網蓋廠糧 網願廠淵製艱淵醖壓膚 (鏇鏇襯壓糧網襯鑰積築 ) | 积极 | 2014-06-01 | |
Midazolam/fentanyl | 積繭構鑰膚淵積衊糧淵(艱鹹選膚遞壓艱憲鬱鏇) = 醖餘鏇艱範觸艱顧衊獵 網願廠淵製艱淵醖壓膚 (鏇鏇襯壓糧網襯鑰積築 ) | ||||||
N/A | 38 | (Ketamine) | 壓淵窪衊鹽願鑰觸網鑰(艱廠觸遞鹽鬱積網蓋夢) = 鏇壓廠鑰選鹹壓鑰壓鹹 願積遞積艱艱廠鏇壓鏇 (觸淵網糧鬱積築願膚壓, 8.11) 更多 | - | 2013-08-06 | ||
(Methohexital) | 壓淵窪衊鹽願鑰觸網鑰(艱廠觸遞鹽鬱積網蓋夢) = 鏇醖鹹壓鑰鏇簾遞願願 願積遞積艱艱廠鏇壓鏇 (觸淵網糧鬱積築願膚壓, 7.70) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用